IL18 and breast carcinoma: Gene expression analysis suggested the potential of NLRP3 inflammasome modulation to counterbalance breast cancer cells growth by activating the immunogenic cell death (pyroptosis) and inhibiting the activity of pro-inflammatory cytokines, IL-1β and IL-18 (Fig. 4).